4//SEC Filing
Reich Kristian 4
Accession 0001213900-25-120105
CIK 0001821586other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 4:29 PM ET
Size
8.2 KB
Accession
0001213900-25-120105
Insider Transaction Report
Form 4
Reich Kristian
Chief Scientific Officer
Transactions
- Sale
Class A ordinary shares, par value $0.0001 per share
2025-12-08$15.08/sh−130,000$1,960,400→ 72,908 total - Sale
Class A ordinary shares, par value $0.0001 per share
2025-12-09$14.43/sh−72,908$1,052,062→ 0 total
Holdings
- 2,974,551(indirect: See footnote.)
Class A ordinary shares, par value $0.0001 per share
Footnotes (3)
- [F1]Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.036949 to $15.101507. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Documents
Issuer
MoonLake Immunotherapeutics
CIK 0001821586
Entity typeother
Related Parties
1- filerCIK 0001920553
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 4:29 PM ET
- Size
- 8.2 KB